Regeneron Pharmaceuticals, Inc.

REGN • Biotechnology

$805.46

▼ -2.02 (-0.25%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$86.24B

Crecimiento

18.8%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 31.4%Flujo de caja libre positivo · 39.01Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 17.92Nivel de deuda manejable · 0.09

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$805.46

Change-0.25%

Shares Out106.80M

Market Cap$86.24B

Enterprise Value$80.95B

52W Range541.00 - 821.11

Beta0.24

P/E19.92

P/S5.55

P/B2.22

P/FCF23.47

EV/Sales5.21

Price$805.46

Change-0.25%

Shares Out106.80M

Market Cap$86.24B

Enterprise Value$80.95B

52W Range541.00 - 821.11

Beta0.24

P/E19.92

P/S5.55

P/B2.22

P/FCF23.47

EV/Sales5.21

EV/EBITDA15.04

EV/FCF22.03

Earnings Yield5.02%

FCF Yield4.26%

Dividend Yield0.34%

Gross Margin85.35%

Oper. Margin24.95%

Profit Margin31.41%

Debt/Eq0.09

Current Ratio4.13

Quick Ratio3.39

Revenue 5Y18.85%

Target$856.80

Target Upside6.37%

Target Median$855.00

Target Range750.00 - 1030.00

Volume1.43M

Avg Volume995.49K

EPS Surprise0.56

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

85/100

Fortaleza financiera

Deuda, caja, estabilidad

95/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

71/100

Por qué este puntaje▼

Márgenes estables o en mejora · 31.4%Flujo de caja libre positivo · 39.01Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 17.92Nivel de deuda manejable · 0.09Liquidez saludable · 4.13

Analyst view

Analyst sentiment and price target

REGN

Analyst sentiment

Based on 49 analyst votes · 2026-10-20

86/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-31

Bajo

$641.00

Promedio

$823.39

Mediana

$839.50

Alto

$1000.00

Resumen de la compañía

IPO: 4/2/1991

Industria: Biotechnology

P/B i: 2.22

Deuda / Patrimonio i: 0.09

Margen operativo: 24.95%

Margen neto: 31.41%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.09

Ratio corriente: 4.13

Ratio rápido: 3.39

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

RYAN ARTHUR F

Transacción: 07/02/2026

VENTA

Cambio

-200

Precio

$650.15

Presentación

07/07/2026

Tipo

VENTA

RYAN ARTHUR F

Transacción: 05/01/2026

VENTA

Cambio

-2

Precio

$714.13

Presentación

05/04/2026

Tipo

VENTA

RYAN ARTHUR F

Transacción: 04/01/2026

VENTA

Cambio

-40

Precio

$779.71

Presentación

04/03/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
RYAN ARTHUR F	VENTA	-200	$650.15	07/02/2026	07/07/2026
RYAN ARTHUR F	VENTA	-2	$714.13	05/01/2026	05/04/2026
RYAN ARTHUR F	VENTA	-40	$779.71	04/01/2026	04/03/2026
RYAN ARTHUR F	VENTA	-20	$789.28	03/02/2026	03/03/2026
Zoghbi Huda Y	VENTA	-1,638	$376.69	02/19/2026	02/23/2026
Zoghbi Huda Y	VENTA	-4	$790.00	02/19/2026	02/23/2026
RYAN ARTHUR F	VENTA	-1	$787.82	02/09/2026	02/11/2026
Pitofsky Jason	VENTA	-1,000	$492.00	02/09/2026	02/11/2026
Pitofsky Jason	VENTA	-53	$785.72	02/09/2026	02/11/2026
Bassler Bonnie L	VENTA	-1,500	$374.12	01/07/2026	01/08/2026
Bassler Bonnie L	VENTA	-1,500	$800.00	01/07/2026	01/08/2026
POON CHRISTINE A	COMPRA	+1,962	$772.76	01/02/2026	01/06/2026
POON CHRISTINE A	COMPRA	+155	Not reported	01/02/2026	01/06/2026
Bassler Bonnie L	COMPRA	+155	Not reported	01/02/2026	01/06/2026
Bassler Bonnie L	COMPRA	+1,962	$772.76	01/02/2026	01/06/2026
BROWN MICHAEL S	COMPRA	+155	Not reported	01/02/2026	01/06/2026
BROWN MICHAEL S	COMPRA	+1,962	$772.76	01/02/2026	01/06/2026
COLES N ANTHONY	COMPRA	+155	Not reported	01/02/2026	01/06/2026
COLES N ANTHONY	COMPRA	+1,962	$772.76	01/02/2026	01/06/2026
RYAN ARTHUR F	COMPRA	+1,962	$772.76	01/02/2026	01/06/2026

Sobre la compañía

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Fuente - Link

Competidores

ALNY ARGX CI COR ELV GMAB IDXX INCY UTHR ZTS

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Regeneron's leading weight-loss candidate could offer patients an option with fewer side effects. The company has another investigational weight-loss medicine designed to help preserve lean muscle mass.

The Motley Fool

Frank Rimerman Advisors LLC Acquires 876 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Frank Rimerman Advisors LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 153.7% in the quarter, according to its most recent 13F filing with the SEC. The firm owned 1,446 shares of the biopharmaceutical company's stock after purchasing an additional 876 shares during the quarter. Frank Rimerman Advisors LLC's holdings

Defense World

Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Insider Sells $3,204,386.90 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) insider Andrew Murphy sold 4,147 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at

Defense World

Regeneron’s Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)

What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares on 10/14/2026. The shares sold for $753.76 to $781.47 each and brought in about $3.20 million, according to the Form 4. The filing says the trades were made under a Rule 10b5-1 trading plan. The same filing shows

Defense World

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Regeneron's revenue is growing at a good clip despite declining Eylea sales. Dupixent is the main reason behind recent strong financial results.

The Motley Fool

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-29	8.91	9.47	0.56
2026-01-30	10.74	11.44	0.7
2025-10-28	9.65	11.83	2.18
2025-08-01	8.43	12.89	4.46
2025-04-29	8.62	8.22	-0.4
2025-02-04	11.21	12.07	0.86
2024-10-31	11.69	12.46	0.77
2024-08-01	10.61	11.56	0.95
2024-05-02	10.17	9.55	-0.62
2024-02-02	10.73	11.86	1.13
2023-11-02	10.72	11.59	0.87
2023-08-03	9.84	10.24	0.4